NPS Pharmaceuticals (NPSP) On Watch on Amgen (AMGN) Sensipar News
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Amgen (AMGN): No Conclusion on Sensipar's Role in Death, Still Working with FDA
February 26, 2013 12:18 PM ESTAmgen, Inc. (NASDAQ: AMGN) says there is no conclusion on Sensipar's role in death outlined by the FDA. The company said it was still working with the FDA on Sensipar development.
Comments were made by a spokesperson via email to Bloomberg.... More
Trials of Amgen's (AMGN) Sensipar Halted Following Death - FDA
February 26, 2013 12:01 PM ESTThe U.S. Food and Drug Administration (FDA) has stopped all pediatric clinical trials of Amgen's (Nasdaq: AMGN) Sensipar (cinacalcet hydrochloride) after the recent death of a 14-year-old patient in a trial. FDA continues to gather information on the circumstances surrounding the patients death. Sensipar is a medication used to decrease the release of parathyroid hormone (PTH) from the parathyroid gland. Sensipar lowers high PTH levels leading to lower calcium levels in the blood; when calcium levels are too low it can result in health problems. FDA has approved Sensipar for use... More
